A247 Bortezomib, Dexamethasone, Cyclophosphamide, Lenalidomide (VDCR) Has High Efficacy in First-Line MM

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma

“…Nonetheless, a key issue to be addressed is reducing the risk of progression within 1-year of treatment initiation in patients with advanced (ISS stage II/III) disease, with or without ASCT. Thus, an important area for future exploration is the addition of other novel therapies and conventional cytotoxic agents, including cyclophosphamide or liposomal doxorubicin, 12,13,32,41,42 as well as newer agents such as histone deacetylase [43][44][45] and heat shock protein 90 inhibitors, 46 which have the potential of not only improving activity by overcoming resistance but also improving the therapeutic index of the combination by reducing toxicity, such as neuropathy. 46,47 In conclusion, lenalidomide-bortezomib-dexamethasone is a highly effective regimen for previously untreated MM, and may represent the basis of future standards-of-care in this setting.…”